Clonal expansion of T cell specificities in the synovial fluid of patients has been taken as evidence for a local stimulation of T cells. By studying the T cell receptor (TCR) repertoire of CD4+ T cells in the synovial and peripheral blood compartments of patients with early rheumatoid arthritis (RA), we have identified clonally expanded CD4+ populations. Expanded clonotypes were present in the peripheral blood and the synovial fluid but were not preferentially accumulated in the joint. Dominant single clonotypes could not be isolated from CD4+ cells of HLA-DRB1*04+ normal individuals. Clonal expansion involved several distinct clonotypes with a preference for V beta 3+, V beta 14+, and V beta 17+CD4+ T cells. A fraction of clonally related T cells expressed IL-2 receptors, indicating recent activation. The frequencies of clonally expanded V beta 17+CD4+ T cells fluctuated widely over a period of one year. Independent variations in the frequencies of two distinct clonotypes in the same patient indicated that different mechanisms, and not stimulation by a single arthritogenic antigen, were involved in clonal proliferation. These data support the concept that RA patients have a grossly imbalanced TCR repertoire. Clonal expansion may result from intrinsic defects in T cell generation and regulation. The dominance of expanded clonotypes in the periphery emphasizes the systemic nature of RA and suggests that T cell 
Introduction
RA is a chronic inflammatory disease of unknown etiology (1) . The presence of CD4+ T cells in the synovial lesions has supported the hypothesis that T helper cells are important in inducing and sustaining the synovial inflammation (2) (3) (4) . Genetic studies identifying a shared sequence polymorphism encoded by the third hypervariable region (HVR)1 of the HLA-DRB1 gene have supported the theory that pathomechanisms in RA are related to the ternary complex formed by HLA mole-cules, antigenic peptides, and interacting T cell receptor (TCR) molecules (5) (6) (7) (8) (9) . In the current paradigm, disease associated HLA-DR molecules function by selecting and presenting arthritogenic antigens to tissue infiltrating T cells. So far, no diseaseinducing antigen has been identified. Recent efforts have focused on analyzing the molecular diversity of the T cell population accumulated in the synovia (10-16). Some, but not all reports have indicated that the diversity of synovial T cells is restricted, raising the possibility that selected T cell specificities encounter antigen in the joint and proliferate. The model of selective representation of some T cell specificities in the synovia, however, has been challenged by a lack of consensus in different reports (17) . A further challenge to the model of a synovia specific T cell response to an arthritogenic antigen comes from the clinical experience that RA is a systemic disease. Morbidity and mortality of the disease are associated with progression of the disease beyond the joint.
Several recent observations are difficult to reconcile with the model that the HLA-DR association of RA solely reflects the selective peptide binding of HLA-DR molecules in the induction or effector phase of the pathogenetic immune response. We have recently described that HLA-DRB 1 alleles influence severity of the disease rather than susceptibility. In particular, a gene dosage effect of HLA-DRB 1 alleles is functional in RA (8, 18) . Patients combining two disease-associated HLA-DRB 1 alleles have not only more severe joint destruction but also a significant risk of developing extra-articular disease. A unique role exists for homozygosity of the HLA-DRB1 *0401 allele, a genotype accumulated in the patient cohort with a very high frequency of rheumatoid vasculitis. We have therefore proposed the alternative model that the contribution of disease linked HLA-DR molecules relates to their role in forming the TCR repertoire (8, 19) .
In studies comparing the synovial and peripheral TCR repertoires in RA patients, we have now made the observation that RA patients carry clonally expanded populations of CD4+ T cells. Expanded clonotypes were highly frequent in the peripheral blood. While they were present in synovial fluid and blood, they were not specifically enriched in the joint. Oligoclonality preferentially involved V,63 +, VP314+, and V,617 + T cells. Different clonotypes fluctuated independently in their frequencies, suggesting that recognition of a single antigen is not the driving force for clonal expansion. These data demonstrate an imbalance in the TCR repertoire of CD4 + helper cells in RA patients which may relate to a defect in generating or controlling diversity of CD4 + T cells.
followed for at least 12 mo to confirm the diagnosis of RA according to the ACR criteria (20) . Control individuals were selected to match the HLA-DRBl alleles of the patient population. They did not have a personal or family history of RA or any other chronic inflammatory disease.
Patients and controls were characterized for their HLA-DRB 1 alleles by allele-specific amplification and subsequent oligonucleotide hybridization as recently described (8, 21) . In brief, DNA was extracted from PBMC and amplified with primer sets specific for the sequence polymorphism in the HVR1 of the HLA-DRB1 alleles. Amplified sequences were subsequently hybridized with oligonucleotides specific for polymorphism of the HVR2 and HVR3. The sequences of the oligonucleotides used have been recently described. The HLA-DRB1 alleles of patients RA-I to RA-5 and the control individuals NP-I to NP-8 were as follows: RA-1, HLA-DRB1 *0404/0404; RA-2, HLA-DRB1 *0101/ 0404; RA-3, HLA-DRB1 *0401/13; RA4, HLA-DRBl *0101/ 13 CD3 for 12 h at a concentration of 1 x 106/ml and then cloned in IL-2 containing medium at 0.5 cell/well. Peripheral T cell clones from patient RA-1 were obtained from three independent experiments to ascertain that the identification of identical clonotypes did not represent an in vitro culture artifact. Established T cell clones were screened for the expression of the CD4 and CD8 markers by FACS analysis. Only cultures which were negative for CD8 cells were further analyzed. T cell clones (58, 70, and 71 clones, respectively) were established from individuals NP-1, NP-2, and NP-3, using the identical procedure described for the RA patients. PBMC from individuals NP-4 and NP-5 were stained with mAb to CD4 (Becton Dickinson, Mountain View, CA) and V,/i17 (Amac Inc., Westbrook, ME) and sorted on a FACSVantage. A minimum of 10,000 V,817' CD4+ T cells was obtained and activated with immobilized anti-CD3 for 12 h in the presence of syngeneic irradiated filler cells. T cells were then cloned as described above.
V,/ gene segment analysis ofT cell clones. Total RNA was extracted from CD4 + T cell clones by guanidinium thiocyanate phenol chloroform extraction using a commercially available kit (RNA Stat; Tel Test, Friendswood, TX). V,/ gene segment usage was determined by reverse transcription PCR with V,/ specific primers and a C/8 specific primer as recently described (22, 23) . Amplified products were separated on 2% agarose gels and identified with ethidium bromide.
TCR sequence analysis of T cell clones. cDNA from selected T cell clones was amplified with a C,/ primer and the appropriate V/i primer attached to a T7 promoter. The amplified product was transcribed using a T7 RNA polymerase and directly sequenced by reverse transcriptase mediated dideoxysequencing as recently described (24, 25 of which were identical. To address the question whether the clonal expansion was specific for the synovial fluid or whether the expanded clonotypes were also found in the peripheral blood, CD4+ T cell clones were established from peripheral blood after polyclonal activation and TCR /B genes from V,614 + and VP17 + T cell clones were sequenced. The sequence data of synovial and peripheral T cell clones are summarized in Tables I and II . Of the four clonotypes found to be expanded in the synovial fluid, two were found to be also dominant in the peripheral blood. In particular, the repertoire of V,617+ T cells in patient RA-1 was highly restricted and was clearly dominated by one clonal specificity which was found in 24 of 30 V/317+ peripheral T cell clones derived from three independent cloning experiments at two different time points (months 2 and 7 after disease onset) and in two out of seven synovial T cell clones. A second expanded clonotype, RA-1-17C, was identified only in the peripheral blood at month 7. Also, the VPB14+ T cell clonotype, which had been isolated from the synovial fluid, was present in the peripheral blood. A very similar picture emerged for patient RA-2. In 52 CD4 + peripheral T cell clones analyzed, we found eight VP 14+ T cell clones and four V,617+ clones. Sequencing subjective symptoms. Serial dilutions of cDNA from the T cell clone expressing the appropriate CDR3 served as positive controls. The probe was specific for CDR3 specific sequences and did not cross-hybridize on a T cell clone sharing the same VB-JB combination but expressing a different junctional sequence. CDR3 specific sequences were detected in CD4+ and CD4+ IL-2R+ PBMC. Frequencies were determined by parallel hybridization of the amplified product with a CP specific probe (data not shown) and by comparing the signal intensities with serial dilutions of the positive control clone. The clonal specificity was not enriched in the IL-2R+ fraction compared to the total CD4 population (24% versus 39% of VB17 transcripts).
Peripheral CD4+ T cells from patient RA-1 were studied over a period of 12 mo. The longitudinal time course of the frequencies of clonal specificity RA-1-17A is given in Fig. 3 . This clonotype represented a substantial proportion of CD4+ Vf317+ T cells which ranged from 30 to 40% in the first 10 mo and increased to over 80% after 15 mo (Fig. 3, upper panel) . Studies with mAb specific for VB17 demonstrated frequencies in the high normal range from 5 to 7% between 2 mo after the disease onset and 10 mo after disease onset. The frequencies increased to 15% V/.317+ T cells of peripheral CD4+ T cells 15 mo after disease onset, at the time when this clonal specificity had expanded to more than 80% of VP(17 + T cells. At any given time point, the clonal specificity was found within the subset of IL-2R+ T cells indicating recent activation (Fig. 3,  lower panel) . No striking correlation between the frequency of the T cell clone within the CD4+ subset and the frequency within the CD4+ IL-2R+ subset was found. In the first 10 mo of disease, the frequency of the clonotype within the IL-2 responsive cells varied between 9 and 34%. 15 mo after disease onset, the clonotype was found only at a frequency of 6% within CD4+ IL-2R+ cells, while at this time point, the frequency of the T cell clone had increased to over 80% of all CD4 + VP317 + T cells.
Distribution of clonally expanded T cells in the peripheral and synovial compartments. The expanded clonotypes were originally isolated from the synovial fluid and subsequently found in high frequencies in the peripheral blood compartment. 
CD4+ T cells (upper panel) and preactivated IL-2R+
CD4+ T cells (lowerpanel) were obtained from peripheral blood of patient RA-I at 2, 7, 11, and 15 mo after disease onset. cDNA was amplified with a V/317 specific primer set and the amplified product was probed with a CDR3 specific and a C/3 specific oligonucleotide as described in Fig. 2 . Frequencies were calculated by comparing the signal intensities with serial dilutions of a positive control clone.
The current paradigm predicts that the disease relevant immune response in RA occurs in the synovial membrane. To address the question whether the expanded clonotypes were accumulated in the synovia or selectively activated in the synovia, we compared frequencies of CDR3 specific sequences in synovial and peripheral T cells. As summarized in Table III , there was no evidence for an enrichment of the sequence specific for the CDR3 of clone RA-1-17A in the synovial fluid. 7 mo after disease onset of patient RA-1, the clone was fivefold more frequent in the peripheral blood compartment than in the synovial fluid. While the clone was present in the IL-2R+ peripheral CD4+ compartment, albeit at a lower frequency than in the IL-2R -compartment, preactivated cells of this particular clonotype were almost undetectable in the synovial fluid. 8 (13, 14, 27) . We have therefore focused our analysis on these VP elements and have used the VP5.1 and V/38 elements as controls. (Table IV) .
bution of TCRs expressing different CDR3 length (data not shown). Direct sequencing of selected V-J combinations confirmed that these Gaussian distributions did not contain an expanded clonal specificity which exceeded 25% of a particular V-J combination and could therefore be detected by direct sequencing. In contrast, deviations from the Gaussian distribution and dominance of one particular CDR3 length was seen for 12 V,/-Jf3 combinations in the three patients (Fig. 4) . Sequencing of these 12 V-J combinations revealed dominant clonotypes in 7 out of the 12 samples sequenced. The TCR sequences are given in Table IV (Table II) 
Discussion
This study identified an abnormality in the TCR repertoire of peripheral CD4+ T cells in patients with early RA. While analyzing the diversity of synovial fluid T cells, we found that several clonotypes in the CD4+ subset had undergone clonal expansion. Expanded clonotypes were not limited to the syno- 
AGC AGT CGC GGA CAG GGA CGG GAT GAG CAG TTC TTC (2.1)
AGT AGT GTA ATT CCG GGA CTA GCG GGC GCG GAG ACA GAT ACG CAG TAT TTT (2.3)
Vf614
AGC AGT CCT TGG GGC TCT TCC TAC GAG CAG TAC TTC (2.7)
AGT AGT ACC CCG GGG CGG GCG AAC ACT GAA GCT TTC TTT (1.1) (28) (29) (30) . The expanded clonotypes described here, however, were present at frequencies 0.1% to higher than 1% of all TCR molecules. Such high frequencies are generally only achieved for antigen specific responses in well defined tissue compartments. The representation of identical TCR clonotypes in the peripheral blood and in the synovial fluid of the two RA patients could be the result of tissue infiltration of T cell specificities expanded in the periphery or the result of recirculation of in situ expanded specificities. The dominance of the clonally expanded T cells in the peripheral blood compartment of all patients and the finding that the clonotype was not enriched in the IL-2R+ compartment of synovial cells make it unlikely that T cells replicate in the synovium and migrate out of the joint. This raises the interesting question of whether expanded T cell clones result from an antigen-driven process and where the clonotypes are expanded.
In vivo TCR repertoire changes of the magnitude as reported here have only been observed after superantigenic stimulation (31). The preferential clonotypic expansion of V/33 +, VP314 +, and VP317 + T cells is an interesting finding and would be compatible with a VP specific mechanism initiating T cell growth. These VP elements share a common structure in the HVR4 of the TCR /3 chain which has been implicated in superantigen binding (32, 33) . Stimulation with a superantigen alone, however, does not result in the selection of dominant clonotypes within one VP element. In addition, we initially did not find a major skewing of the VP3 and VP317 frequencies when analyzed with anti-TCR mAb (data not shown). Only after one clonotype reached more than 80% of the VP317 subset did we detect increased frequencies of VP317 + CD4+ T cells in the blood. It is possible that the initial stimulus was provided through a superantigen followed by clonal selection and expansion. Experiments in murine models have suggested that exposure to a superantigen induces T cell proliferation followed by deletion of all T cell specificities except the ones which encounter antigen (34) (35) (36) . This mechanism has been recently proposed to play a role in the pathogenesis of RA (13) . In this model, we would have missed the time of superantigenic expansion, but would have captured the stage of antigenic selection in the patients described here. It is of particular interest to note that Vf3 +, VPl 14+, and V/317 + T cell clones have been implicated by a number of investigators in synovial inflammation in RA (13, 14, 26, 37) .
Clonal abnormalities of circulating T cells have been previously described in RA patients. These clonal expansions have been limited to CD8 + T cells. Generally, clonality among CD8 + T cells has been associated with Felty's syndrome (38, 39) . In a subset of these patients, clonality in the CD8 + subset has been linked to increased numbers of large granular lymphocytes (38) . Clonal expansion within the CD8 population has also been described in Felty's patients who do not present with an expansion of large granular lymphocytes (40). It has been proposed that such expanded clonotypes might exhibit suppressive or cytotoxic effector functions in the bone marrow resulting in a suppression of the granulopoiesis. In general, patients with Felty's syndrome have longstanding RA. Thus, the emergence of clonal CD8 + specificities may be a consequence of the chronic inflammatory response in these patients. It is, however, of interest to note that most of the patients with Felty's syndrome, as patients with other extra-articular rheumatoid organ manifestations, carry a double dose of disease associated HLA-DRB1 alleles (41) . Three of the five patients described in this study also expressed two disease-associated HLA-DRB 1 alleles and one of these patients, RA-1, has already developed extra-articular manifestations in the early stages of disease.
DerSimonian et al. (42) have suggested that the clonal expansion of CD8 clonotypes may not be restricted to patients with Felty's syndrome but may be a more generalized feature of patients with RA. These authors have used mAbs to the Vdl2 element to identify RA patients with largely increased numbers of Val2+ CD8+ T cells in the peripheral blood. Sequence analysis confirmed the dominance of single clonotypes in these expanded T cell populations. Clonal expansion was found in 10% of the RA population studied. None of the patients presenting with clonally expanded CD8 + T cells expressed the disease associated HLA-DR "shared epitope" on both haplotypes. Dominant clonotypes within the CD8 subset have also been identified in normal donors, although it appears to be a more prominent finding in RA (43, 44). There is emerging evidence that the repertoire of CD8+ T cells is smaller than expected and that clonal dominance, at least as a transient phenomenon, is not unusual. In contrast, clonal expansion within the CD4 subset appears to be a very unusual finding.
The expanded clonotypes described in this study expressed the CD4 marker and were negative for the CD8 marker. All of them were isolated from patients with very early disease. Thus, these CD4+ clonally expanded T cell populations are unlikely a result of chronic disease. Their presence during very early disease rather raises the possibility that they are involved in inducing disease. Dominant CD4 + T cell clonotypes are clearly not restricted to early disease but persist over time (Fig. 3) and can also be found in patients with established disease (unpublished observations). The independent fluctuation of two clonotypes further challenges considerations that clonal expansion results from T cell recognition of an arthritogenic antigen. Clone RA-1-17C fluctuated in a pattern resembling disease activity, whereas clone RA-1-17A did not (Table V) . 7 mo into the disease, patient RA-l had highly active disease with polyarthritis, anemia, and peripheral neuropathy documented by electromyography. At 
